New drug cocktail shows promise in tough lung cancers

NCT ID NCT04924192

Terminated Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called TQB3616 combined with either anlotinib or standard chemotherapy in 21 people with advanced lung cancer that had already been treated. The goal was to see if the combination could shrink tumors or slow the cancer's growth. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung carcinoma non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LUNG CARCINOMA

Contacts and locations

Locations

Chongqing University Cancer Hospital

Chongqing, Chongqing Municipality, 400000, China
Guizhou Provincial People's Hospital

Guiyang, Guizhou, 550002, China
Sichuan Cancer Hospital

Chengdu, Sichuan, China
The First Hospital of Lanzhou University

Lanzhou, Gansu, 730000, China
The Second Affiliated Hospital of PLA Air Force Military Medical University

Xi’an, Shanxi, 710038, China
West China Hospital of Sichuan University

Chengdou, Sichuan, 610041, China
Yunnan Cancer Hospital

Kunming, Yunnan, 650011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.